upfront
hot off the press
HIV-1 RNA within incoming particles to cDNA occurred normally, whereas integra-tion of HIV-1 proviruses into the host cell genome was markedly diminished in MxB-expressing cells. An MxB-dependent reduc-tion of HIV-1 2-long terminal repeat circles was also observed by Goujon et al and Kane Oliver T. Fackler & Oliver T. Keppler
MxB/Mx2: the latest piece in HIV’s interferon puzzle
O
ur innate immune system consti-tutes a first line of defence against invading microorganisms, long before pathogen-specific adaptive immune responses become effective. Intense global research efforts over the past 30 years have deepened our understanding of the molecu-lar principles that underlie the early innate recognition of evolutionarily conserved structures on pathogens, the signalling cas-pathogens, the signalling cas-cades this elicits, and the proinflammatory mediators and host cell effectors that inhibit pathogen replication. On the other side of the coin, microbes have evolved strategies to circumvent these processes, an understand-ing of which could enable new therapeutic approaches. Innate pathogen recognition by the host typically results in the expression of proinflammatory cytokines, which orches-trate early defence mechanisms to infection. A characteristic of this response is the secre-tion of interferons (IFNs), named after their capacity to ‘interfere’ with viral replication in host cells through the induction of IFN-stimulated genes (ISGs). Three reports from the Malim, Bieniasz and Liang labs, pub-lished in Nature and Cell Host & Microbe, now describe human MxB/Mx2 as a potent IFN-induced inhibitor of the early phase of human immunodeficiency virus 1 (HIV-1) infection in target cells [1–3].Landmark studies of influenza viruses in the 1980s identified the murine myxo-virus resistance protein 1 (Mx1) as the first cellular ISG with potent antiviral activity, which is conserved in the human orthologue MxA [4]. MxA is a GTPase of the dynamin superfamily, the expression of which is potently induced by type I and type III IFNs. MxA multimers apparently adopt ring-like structures that allow them to function as restriction factors for influenza viruses by binding to incoming viral capsids [5]. In addition to MxA, humans encode for a sec-ond Mx protein, MxB, also referred to as Mx2. Despite having 63% sequence identity with MxA, MxB was reported not to have antiviral activity against influenza or vesicu-lar stomatitis virus [6], and its biological role has remained largely elusive.1030 EMBO reports VOL 14 | NO 12 | 2013 ©2013 EUROPEAN MOLECULAR BIOLOGY ORGANIZATION
et al [1,3], but not by Liu et al [2]. This HIV-1 cDNA species acts as a quantitative marker
In contrast to the influenza virus field, for successful nuclear import of the reserved
studies on HIV for many years focused on transcribed viral genome in infected cells. strategies to induce broadly effective adap-These results place the anti-HIV activity of
tive responses and to interfere with cellular MxB in the post-entry phase of HIV-1 infec-cofactors of infection. The interest in innate tion after cDNA synthesis, possibly involv-immunity against HIV was spurred by the ing nuclear import, nuclear stability and/characterization of potent anti-HIV activity or integration of the viral cDNA (Fig 1).
by IFNs in tissue culture models, the detec-Analysis of a broad range of primate lentivi-tion of strong proinflammatory cytokine/ ruses and retroviruses revealed that human IFN responses in patients during the acute MxB potently inhibits HIV-1, HIV-2 and
phase of HIV-1 infection, and the identifi-simian immunodeficiency virus, has a lower
cation of several IFN-inducible restriction effect on the infection by feline immuno-factors—including APOBEC3 proteins, deficiency virus and equine infectious anae-TRIM5a, SAMHD1 and BST2/CD317/teth-mia virus, and only marginal or no activity
erin— that target HIV-1 at early and late against murine leukaemia virus.
steps of the replication cycle (Fig 1) [7]. Two experimental approaches were However, these restriction factors cannot taken to define the viral component tar-fully account for the anti-HIV state elic-geted—directly or indirectly—by MxB and
ited in HIV target cells by IFN. As a conse-gain a first insight into its mode of action.
quence, systematic efforts were launched to HIV-1 capsid protein is known to play a cen-identify additional ISGs with anti-HIV activ-tral role in mediating physical interactions
ity. Overexpression screening approaches with several host proteins involved in the to test the antiviral activity of more than 380 post-entry phase of infection, so the Malim human ISGs initially reported that MxB has and Bieniasz laboratories [1,3] focused their
some antiviral activity against HIV-1 [8], as attention on this component of the viral well as against vesicular stomatitis virus and reverse transcription complex (RTC)/pre-mouse herpes virus type 68 [9]. integration complex (PIC). They identified The Malim and Bieniasz labs used com-residues in capsid that are involved in bind-parative gene expression profiling in cell lines ing to cyclophilin A (CypA), TRIM5a, TNP03, that differed in their capacity to restrict the CPSF6, NUP153 and NUP358/RanBP2, as early post-entry phase of HIV infection after also critical for the sensitivity of HIV-1 to type I IFN treatment as an unbiased screening the antiviral action of MxB. Consistently, the approach for ISGs with anti-HIV activity [1,3]. study by the Liang laboratory [2] observed
Both of these studies, as well as the one from that passaging HIV-1 in SupT1 T cells, which the Liang lab [2], showed that ectopic overex-constitutively express high levels of MxB,
pression of MxB potently reduces the permis-resulted in the rapid emergence of HIV-1
siveness of the cells in a single-cycle HIV-1 variants that had similar mutations in capsid. infection assay and results in a pronounced Thus, the viral capsid governs the sensitivity reduction of virus spread over multiple of HIV-1 to MxB. Furthermore, the results rounds of replication. Moreover, silencing obtained by Liu and colleagues indicate of MxB expression by RNA interference in that the action of MxB might be associated type I-IFN-treated cells markedly reduced the with that of CypA, as silencing of CypA inhibitory potency of the cytokine, pinpoint-expression or disruption of the capsid–
ing MxB as an important IFN effector with CypA interaction by addition of the immuno-anti-HIV-1 activity. suppressive drug cyclosporine A abrogated Next, the three groups addressed which the anti-HIV activity of MxB. Moreover, specific post-entry step of the HIV repli-expression of a recombinant CypA–MxB
cation cycle is affected by MxB expres-fusion protein significantly increased the
sion by using established quantitative PCR antiviral potency of MxB, presumably by methodology. Reverse transcription of the facilitating its tethering to the RTC/PIC.
热门文档